This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forrest, G. N.
Right arrow Articles by Tamura, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Forrest, G. N.
Right arrow Articles by Tamura, K.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2010, p. 14-34, Vol. 23, No. 1
0893-8512/10/$12.00+0     doi:10.1128/CMR.00034-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Rifampin Combination Therapy for Nonmycobacterial Infections

Graeme N. Forrest1,2* and Kimberly Tamura1

Portland Veterans Affairs Medical Center,1 Oregon Health and Science University, Portland, Oregon2

Summary: The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

* Corresponding author. Mailing address: Portland Veterans Affairs Medical Center, 3701 SW US Veterans Hospital Rd., Mail Code P3-ID, Portland, OR 97239. Phone: (503) 220-8262, ext. 152118. Fax: (503) 273-5348. E-mail: forrestg{at}ohsu.edu

Clinical Microbiology Reviews, January 2010, p. 14-34, Vol. 23, No. 1
0893-8512/10/$12.00+0     doi:10.1128/CMR.00034-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»